Development Pipeline

Here are the key clinical studies in indications for which the Sumitomo Pharma Group aims to obtain approval. The study for the most advanced development stage is listed if there are multiple studies with the same region and indication.

As of May 13, 2026

Drug Candidates in Development

  • Psychiatry & Neurology
    (Small molecule)     Number of compounds under development

    0

  • Psychiatry & Neurology
    （Regenerative medicine / cell therapy）     Number of programs
     

    0

  • Oncology
          Number of compounds under development

    0

  • Others
          Number of compounds under development

    0

Psychiatry & Neurology

Brand name/Generic name/Product code Planned indication(s) Development stage
Small molecule
LATUDA®/Lurasidone hydrochloride (New dosage and administration: pediatric) Schizophrenia Submitted (March 2026)
DSP-0038 Alzheimer’s disease psychosis Phase 1
DSP-0187 Narcolepsy Phase 1
DSP-3456 Treatment resistant depression Phase 1
DSP-0378 Progressive Myoclonic Epilepsy
Developmental Epileptic Encephalopathy 		Phase 1
DSP-2342 To be determined Phase 1
DSP-0551 Tremor associated with Parkinson’s disease Phase 1
Regenerative medicine / cell therapy
(Collaboration with RACTHERA Co., Ltd.) 		AMCHEPRY®/Raguneprocel/CT1-DAP001/DSP-1083
(Allogeneic iPS [induced pluripotent stem] cell-derived dopaminergic neural progenitor cells) (JAPAN) 		Parkinson’s disease Conditional and time-limited approval (March 2026) Post-marketing clinical study
Raguneprocel/CT1-DAP001/DSP-1083
(Allogeneic iPS cell-derived dopaminergic neural progenitor cells) (U.S.) 		Parkinson’s disease
Phase 1/2
(Investigator-initiated study)
Phase 1/2
(Company-sponsored clinical study)
HLCR011
(Allogeneic iPS cell-derived retinal pigment epithelial cells) (JAPAN) 		Retinal pigment epithelium tear Phase 1/2
DSP-3077
（Allogeneic iPS cell-derived retinal sheet） (U.S.) 		Retinitis pigmentosa Phase 1/2

Oncology

Brand name/Generic name/Product code Planned indication(s) Development stage
Enzomenib Acute leukemia Phase 2
Nuvisertib Myelofibrosis Phase 1/2
SMP-3124 Solid tumors Phase 1/2
DSP-0390 Glioblastoma Phase 1

Others

Brand name/Generic name/Product code Planned indication(s) Development stage
KSP-1007 Complicated urinary tract infections
Complicated intra-abdominal infections
Hospital-acquired bacterial pneumonia including ventilator-associated bacterial pneumonia 		Phase 1
fH1/DSP-0546LP Influenza virus prophylaxis Phase 1